Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05653219 · ClinicalTrials.gov registry record · Phase 3

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

A Phase 3 study of Primary Immune Thrombocytopenia, sponsored by Novartis Pharmaceuticals.

Active
Registry status
Phase 3
Development phase
152
Enrollment target
20
Study locations

NCT05653219 is a Phase 3 study of Primary Immune Thrombocytopenia that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 152 participants, above the 102-participant average among 4 other Primary Immune Thrombocytopenia trials with a reported enrollment target (49% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05653219, a Phase 3 study of Primary Immune Thrombocytopenia, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
152 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the effect of two different doses of ianalumab added to eltrombopag to prolong Time to Treatment Failure (TTF) in adults with primary ITP who failed previous first-line treatment with steroids.

Conditions Studied

Primary Immune Thrombocytopenia

Interventions

  • DRUG Placebo
  • DRUG Eltrombopag
  • BIOLOGICAL Ianalumab

Study Locations (20)

Other

  • Novartis Investigative Site - CABA
  • Novartis Investigative Site - Vienna
  • Novartis Investigative Site - Beijing
  • Novartis Investigative Site - Jinan
  • Novartis Investigative Site - Tianjin

Massachusetts

  • Boston Medical Center - Boston
  • UMASS Memorial Medical Center - Worcester

New York

  • Hematology Oncology Association of Rockland - Nyack
  • Montefiore Medical Center - The Bronx

Arizona

  • Yuma Regional Medical Center - Yuma

Colorado

  • University of Colorado Anschutz - Aurora

Illinois

  • NorthShore University Health System - Evanston

Michigan

  • Michigan Center of Medical Research - Farmington Hills

Montana

  • St Vincent Frontier Cancer Center - Billings

Trial Details

FieldValue
Enrollment Target 152 participants
Start Date 2023-02-02
Est. Completion 2028-04-08
Phase Phase 3

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05653219

The ClinicalTrials.gov registry entry for NCT05653219 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 102-participant average among 4 other Primary Immune Thrombocytopenia trials with a reported enrollment target (49% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Primary Immune Thrombocytopenia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT05653219 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Massachusetts, New York.

Frequently Asked Questions

What is clinical trial NCT05653219 about?

NCT05653219 is a clinical study titled "A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids". The purpose of this study is to evaluate the effect of two different doses of ianalumab added to eltrombopag to prolong Time to Treatment Failure (TTF) in adults with primary ITP who failed previous first-line treatment with steroids.

What is the current status of trial NCT05653219?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 152 participants. The study started on 2023-02-02. Estimated completion is 2028-04-08.

What conditions does trial NCT05653219 study?

This clinical trial studies the following conditions: Primary Immune Thrombocytopenia.

What interventions are being tested in trial NCT05653219?

The interventions under investigation include: Placebo (DRUG), Eltrombopag (DRUG), Ianalumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT05653219?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05653219 being conducted?

This trial has 20 study locations across Arizona, Colorado, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Primary Immune Thrombocytopenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Primary Immune Thrombocytopenia

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.